Transcript Growth(NoTP)

Growth Patterns of Experimental and
Clinical Malignancies
In Vivo
Folder title: Growth(NoTP)
Updated: March 16, 2015
Pre-Clinical Breast Carcinoma
(from Gullino, Cancer, 39:2697-2703)
103
Questions About
Neoplastic Cell Growth
How do we measure neoplastic cell growth?
• In Vitro in cell culture or in tissue culture?
• In vivo in animals?
• In vivo in patients?
What are cancer growth patterns like?
What causes the patterns of growth that we see?
What maintains those growth patterns?
Can we alter those patterns to benefit patients?
Measurement of Cancer Growth
In Cell Culture
• Cell numbers vs time
• Colony formation assays
• Labelled thymidine incorporation
• Dye reduction assays for viable cells
(Dye reduction by mitochondrial activity)
• Dye exclusion assays by viable cells
(Dye exclusion by intact plasma membranes)
In Vivo in Experimental Animals
• Time to appearance of measurable tumor nodules
• Dimensions of tumor nodules with time
• Measurement of tumor products (e.g tumor antigens)
• Host survival time
• (Some guidelines on experimentation with live animal
models, survival assays, and compassionate euthanasia)
Human U937 Leukemia Cells
Cloned in Soft Agar
200 Cells Cloned
Per Tube.
Stained with
pINT (tetrazolium
dye).
Clones
counted:
106
110
Cloning Efficiency:
53%
55%
Control of Tumor Growth Rate In Vivo:
Cell Production
Cell cycle Time
Growth Fraction:
Proportion of Cells in the Cell Cycle to
those in Go (not cycling)
Proportion of Clonogenic Stem Cells
• Clonogenic Stem Cells
• Probability of cell renewal:
• 0.5 = No net growth
• 1.0 = 100 billion cells after 36 divisions
As for bacteria
No cell death
No cell differentiation
• 0.51 = 100 billion cells after 1500 divisions
inexorable, slow, relentless growth vs rapid exponential growth
implications for therapy
Proliferation Control Differences:
Normal Cells vs Neoplastic Cells in Cell Culture
Density-dependent Inhibition of Mitosis:
(Contact Inhibition of Mitosis)
• Normal Fibroblasts: 40,000 cells/cm2
• Virally Transformed Fibroblasts: 4 million cells/cm2
Anchorage-Dependent Effects on Proliferation
• Normal Cells
Grow Attached and Flattened
Stop Dividing When Rounded by Contact
Stop Dividing if Artificially Rounded even with no Contact
Restart Dividing when monolayer is "wounded"
• Transformed Cells
Grow Attached and Flattened
Keep Growing when rounded by contact (overgrow)
Keep growing if artificially rounded even wth no contact
Will form colonies in viscous (semi-solid medium)
Control of Tumor Growth Rate In Vivo:
Consequences for Concepts of Cancer Treatment
Concepts Involving Chemotherapy
• Use and limitations of cell-cycle specific agents
• Re-seeding of tumor growth by non-cycling cells
Concepts Involving Tumor Progression
• Cell Loss and Cell Selection
• A Microcosm of Evolution
Options for In Vivo Therapeutic Control
• Anti-angiogenesis
• Promotion of apoptosis (programmed cell death)
• Exploitation of tumor micro-environment: pH
• Tumor necrosis factor
• Combination chemotherapy
• Cell Synchronization and Cell-cycle-specific treatments
• Host response modification
• Induction of Differentiation
• Targeting the cancer cell phenotype: e.g cell size and cell division
Managing Cancer Development, Progression and Growth In Patients
Inhibit Cell Production!
Promote Cell Loss!
Drive out of the Cell Cycle
Induce differentiation toward normal
Control of Tumor Growth Rate In Vivo: Cell Loss
Cellular Anaplasia
• Disrupted Cytoskeletal Structures
• Aberrant Mitoses
• Nuclear Abnormalities
Positional Anaplasia
• Poor Blood Supply; Aberrant Vasculature
• Low Oxygen Tension, Acidic pH
Host anti-Tumor Responses
• Hormonal Effects
• Immunological Effects
Retained Ability to Respond to Normal Signals
Apoptosis: Genetically Programmed Cell Death
Retained Recognition of Cell Senescence Programs
Applications in Chemotherapy, Radiation Therapy, and
Immunotherapy
Control of Tumor Growth Rate In Vivo:
Inhibit Aberrant Cell Production
Blocking hormone access for hormone-dependent cancers.
Induction of differentiation with cytokines or other signals.
Block aberrant cell signaling pathways
Two Turning Point Questions.
Please put away all other stuff.
Human U937 Leukemia Cells
Cloned in Soft Agar
When you count the
stained colonies there
are 110 colonies per
tube.
200 Cells Cloned
Per Tube.
Stained with
pINT (tetrazolium
dye).
What is the cloning
efficiency of these
leukemia cells in this
system?
(Please respond on
the next slide which
is a Turning Point
Question Slide)
Cloning Efficiency:
53%
55%
Pathological Effects of Cancer
on the Host
Inflammation:
Macrophage, Granulocyte Infiltration, Cytokine Production
Cachexia (Wasting)
Hemorrhaging and Clotting
Immunosuppression
Infection
Pathological Production of Hormones and Other Bio-active
Agents
Loss of Essential Functions: Tissue Destruction and Vital Organ
Failure
Duke University Medical Center
Dr. Henry Friedman
Glioblastoma and Glioblastoma Multiforme
Interveiwed by Dr. Sanjay Gupta
2010
http://www.youtube.com/watch?v=n1Z8yMxSf5E
Preferential Destruction of Leukemia Cells Based on Size:
Untreated Human Promyleocytic Leukemia Cells
vs
Cells Treated with Microfilament-Directed Agent
(Cytochalasin B) to Produce Leukemia-specific Cell
Enlargement
Application of Colony-Formation Assay in Monitoring Effects
of Chemotherapy-Physicotherapy
Of Leukemia Cells in Cell Culture
Untreated U937 cells are
reduced in cloning efficiency
by less than 20% when
sonicated for 4 minutes at 20
watts
Seeded 200 Cells
Drug Treated
Drug Treated and Sonic Treated
Seeded 400 Cells
Cloning efficiency of U937 cells treated for 12 hours with 2 uM CB is cut by 60% with sonication for 4 minutes.
This compares to 20% reduction in clonogenicity of untreated U937 cells or 40% reduction with drug-treatment alone.
Some Thoughts on Physical Approaches to the Management of Cancers:
Leukemias and Blood-borne of Lymphatic Fluid Metastases
Application from outside of the patient
Precise control of dosage
Opportunity for repetitive treatment
Whole body application
Directed appendage application
Application to extra-corporeal shunt
Evasion of chemically-based drug resistance
(unless combined with chemotherapy to alter size)
Monitoring Growth in the Therapy of Mammary
Carcinomas Lacking BRCA2 Mediated DNARepair Capacity
Chemotherapy Directed Toward Defective BRCA-1 and BRCA-2
Genes in Breast and Ovarian Cancers
(See Figure 12-40 and Sidebar 12.11, p. 520 Weinberg)
Propositions:
1. Redundant DNA-repair mechanisms needed by both normal and neoplastic
cells to repair DNA lesions incurred normally during cell division.
2. Repair of damaged DNA is even more important if chemotherapy with
DNA-directed anticancer agents or radiation therapy is being carried out.
3. One type of DNA repair involves poly-ADP-ribose polymerase (PARP).
4. BRCA-1 and BRCA-2 have DNA repair functions as “Housekeeping genes”.
5. Normal cells can use BRCA-1 and BRCA-2 repair functions as well as PARP
repair mechanisms.
6. Breast and Ovarian cancer cells lacking BRCA-1 and BRCA-2 must rely on
the PARP repair option.
7. What happens if one inhibits the PARP repair function using PARP inhibitors,
especially during treatment with agents damaging DNA?
Filename: BRCA2Therapy.ppt
Figure 12-40 Weinberg
Cells lacking BRCA-2 (red line) are
killed off (2 log kill or 99% kill) at
10E-7 M (0.1 uM) anti-PARP drug
concentration. Anti-PARP prevents
DNA repair. (The structure of the
inhibitor is not specified).
Cells with BRCA-2 repair (blue or
green lines) can survive almost
1,000-fold higher concentration of
anti-PARP agent (10E-4M or 100
uM) because they can use BRCA-2
for DNA repair.
If both repair options are blocked
the cancer cells die at low drug
concentration of anti-PARP agent
PARP = poly-ADP-ribose DNA
repair enzyme
BRCA2 = breast cancer
associated antigen involved in
DNA damage repair.
Turning Point Question
Please clear your desk of
everything except your
NXT Transmitter
A visit to the place where Hana Leon, homeless, froze to death
The place where Hana Leon, 42, homeless, died on Feb. 27. She was found under the evergreen by a passerby. (Dennis Nett |
[email protected])
By Steve Carlic | [email protected]
on March 12, 2014 at 8:11 AM, updated March 17, 2014 at 9:33 AM
Hana Leon died in a place you would never want to.
She died on Feb. 27, beneath a small, ornamental evergreen, tucked behind a decorative brick wall that marks the
entrance to Franklin Square. It's on the west side of Franklin Street, beside the on-ramp to S. West Street. There's a
black and gold plaque attached to the brick that recognizes the 1990 National Economic Development Partnership
Award given to the city of Syracuse and Pyramid Companies for restoring the neighborhood.
From where she lay, if you looked to the right you can see the old Learbury building, and ahead the brick facades of
refurbished factories.
On Tuesday the only thing remaining at the spot were a dozen or so plastic bags stuffed with some socks, moldy food
and handfuls of smaller plastic bags. It's not clear if these were Leon's worldly possessions or if they were dumped
there since by somebody else.
Authorities say they think Leon, 42, died of hypothermia. She was found following a frigid night where the low was
minus 8 degrees with the windchill.
Leon suffered from severe paranoid schizophrenia. She was among the 100 or so chronically homeless who live in
Syracuse, where five homeless people have died over the past two winters.
Dr. Friedman proposed several approaches to managing brain
cancers.
Identify any one of those approaches.
Rank
1
Responses
2
3
4
5
6
0%
0%
0%
0%
0%
0%